Navigation Links
AlphaRx Provides Corporate and Development Update
Date:5/20/2008

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to provide shareholders with an update on recent corporate developments.

TSX Venture Exchange Application

--------------------------------

AlphaRx is seeking a listing with the TSX Venture Exchange. Research Capital Corporation is sponsoring the application. AlphaRx is in the process of raising up to $1,800,000 U.S. via a private placement in conjunction with the listing application. AlphaRx has been in correspondence with the TSX Venture Exchange and has responded to all comments raised to-date.

Corporate Website

-----------------

AlphaRx is working on a new and improved corporate website which will reflect all current business focus. This new website will be launched some time in June.

Product Development

-------------------

AlphaRx's current focus is on the development of "nanobiotics" for the treatment of severe pneumonias. AlphaRx's high-priority development programs include Vansolin(TM) and Zysolin(TM).

Vansolin(TM), a specially-formulated Vancomycin nano-particulate formulation, is intended for the treatment of severe pneumonias caused by MRSA (Methicillin Resistant Staphylococcus Aureus) pathogens. Vansolin(TM) is undergoing pivotal animal studies. The Company will make a go/no go decision based on the outcome on these studies which will be available by mid-July.

Zysolin(TM), a specially-formulated Tobramycin nano-particulate formulation, intended for the treatment of severe pneumonias caused by gram negative pathogens such as Psedomonas Aeruginosa. The Company is developing Zysolin(TM) as a primary therapy for Cystic Fibrosis and an adjunctive therapy for ventilated patients with hospital-acquired, Gram-negative pneumonias. Zysolin(TM) is undergoing pivotal animal studies.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Copyright @ 2008. AlphaRx Inc.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRxs Indaflex(TM) Continues its Clinical Development
2. AlphaRx CEO Accumulates More Company Shares
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx Announces Debt Conversion
5. AlphaRx To Present at 47th Annual ICAAC
6. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
7. Cipher provides regulatory update for CIP-TRAMADOL ER
8. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
9. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
10. Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain
11. Dubai Provides Aid for Cyclone Nargis Victims In Myanmar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift ... can be wheeled out of the way and stored when not in use. It is ... the feedback from customers into specific enhancements and created a new product that is built ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... ... ... Land of More and More”: a brilliant story for children and adults alike ... achievable answer. “The Land of More and More” is the creation of published author, ... where he works with the children’s ministry department. , Michael says that he ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... & Faruqi, LLP, a leading national securities law firm, reminds ... KMPH ) of the federal securities class action lawsuit ... underwriters of the Company,s April 16, 2015 Initial Public Offering ... The lawsuit has been filed in the ... on behalf of all those who acquired KemPharm ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
(Date:1/19/2017)... Germany Cataract Surgery Devices ... report, "Germany Cataract Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic ... and distribution shares data for each of these market ...
Breaking Medicine Technology: